Acorda Therapeutics (NASDAQ: ACOR)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Acorda Therapeutics Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Acorda Therapeutics Company Info
A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.
News & Analysis
Even as the market fell again, these stocks posted gains. Find out why.
Wall Street is increasingly concerned about this biotech stock's future.
Shares retreated after the company provided Wall Street with an updated regulatory timeline. Here's what investors need to know.
Find out which of these companies lost the most ground.
The company could face stiff competition following an unfavorable ruling by an appeals court.
The company's lawyers made a last-ditch effort to save previously invalidated patents for a key drug.
An important player in the neuroscience field appears interested in acquiring the troubled drugmaker.
The company provided an update on one of its lead drug candidates.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
ACOR earnings call for the period ending June 30, 2019.
ACOR earnings call for the period ending March 31, 2019.
ACOR earnings call for the period ending December 31, 2018.
ACOR earnings call for the period ending September 30, 2018.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.